Ancora Heart today announced it appointed David Tucker as chief financial officer.
Tucker will be responsible for the Santa Clara, California-based company’s financial strategies and operations as it enrolls patients in the Corcinch-HF pivotal clinical trial of its AccuCinch ventricular restoration system.
“David’s experience includes providing financial leadership across a broad spectrum of companies at a variety of stages, including both public and private life sciences organizations, and we are thrilled to have him join our team,” President and CEO Jeff Closs said in a news release. “While our current clinical focus is on the Corcinch-HF pivotal trial, we are also looking toward the future, which includes a goal of eventual commercialization. David’s expertise in financial planning, operations, and fundraising for organizations pioneering novel therapeutics make him an excellent person to have at the helm of our finance function during this next phase of growth.”
Ancora Heart designed the AccuCinch system to treat the enlarged left ventricle in patients with symptomatic heart failure and a reduced ejection fraction. It improves the structure and function of the heart and brings relief to patients in a transcatheter procedure.
“Ancora Heart is at a very exciting point in its growth pathway, and I am excited to be joining the team at this stage,” said Tucker. “The core values of the Ancora team, which are focused on helping patients live healthier lives, align strongly with my own. I believe that the AccuCinch system has great potential as a treatment option for patients with heart failure and look forward to this opportunity to provide financial leadership to the company.”
Tucker has more than 20 years of experience in financial leadership for life sciences companies. Prior to joining Ancora Heart, he was VP of finance at Atara Biotherapeutics. He is also president and chair of the board of the Northern California Chapter of the Association of Bioscience Financial Officers. Tucker has also previously served varying financial leadership roles at Sunesis Pharmaceuticals, CymaBay Therapeutics, Nuvelo and IntraBiotics Pharmaceuticals.
